INIS
reduction
100%
patients
100%
doses
100%
reviews
100%
psoriasis
100%
interleukins
45%
implementation
18%
cost
13%
guidelines
13%
barriers
9%
safety
9%
assessments
9%
uptake
9%
Keyphrases
Dose Reduction
100%
Plaque Psoriasis
100%
Dose Reduction Strategies
26%
Psoriasis Severity
26%
Area Index
26%
Psoriasis Area
26%
Severity Index
26%
Interleukin-12 (IL-12)
26%
Interleukin-17 (IL-17)
26%
Dermatology Life Quality Index
13%
Interleukin
13%
Guselkumab
13%
Scoping Review
13%
Physician Global Assessment
13%
Cost Reduction
6%
Successful Implementation
6%
Safety Cost
6%
Index Score
6%
Patient Education
6%
TNF Inhibitors
6%
Literature Update
6%
Cost-effectiveness
6%
Literature Search
6%
Clinical Efficacy
6%
On Demand
6%
Randomized Prospective Study
6%
Retreatment
6%
Cost Savings
6%
Lack of Time
6%
Fixed-dose Combination
6%
Medicine and Dentistry
Psoriasis Vulgaris
100%
Drug Dose Reduction
100%
Biological Product
100%
Psoriasis Area and Severity Index
21%
Interleukin 12
21%
Interleukin 17
21%
Tumor Necrosis Factor
15%
Guselkumab
10%
Cytokine
10%
Dermatology Life Quality Index
10%
Health Care Cost
10%
Cost-Effectiveness Analysis
5%
Retreatment
5%
Prospective Study
5%
TNF Inhibitor
5%
Bovine Serum Albumin
5%
Dosing Studies
5%